Psychoeducation improves hepatitis c virus treatment during opioid substitution therapy: A controlled, prospective multicenter trial

Clinical Infectious Diseases

Volumn 57, Issue SUPPL.2, 2013, Pages

  Reimer, Jens ^a   Schmidt, Christiane Sybille ^a   Schulte, Bernd ^a   Gansefort, Dirk ^a   Gölz, Jörg ^b   Gerken, Guido ^c   Scherbaum, Norbert ^d   Verthein, Uwe ^a   Backmund, Markus ^e  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Praxiszentrum Kaiserdamm   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antiviral treatment; Hepatitis C; Injection drug users; Psychoeducation; Retention

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CONTROLLED STUDY; DISTRESS SYNDROME; FEMALE; GENOTYPE; GERMANY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL STRESS; MULTICENTER STUDY; OPIATE SUBSTITUTION TREATMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOEDUCATION; TREATMENT RESPONSE;

ANTIVIRAL TREATMENT; HEPATITIS C; INJECTION DRUG USERS; PSYCHOEDUCATION; RETENTION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; BEHAVIOR THERAPY; FEMALE; GERMANY; HEPATITIS C; HUMANS; INTERFERON-ALPHA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; POLYETHYLENE GLYCOLS; PROSPECTIVE STUDIES; RECOMBINANT PROTEINS; RIBAVIRIN; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 84880973060     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit307     Document Type: Article

References (19)

1. Aceijas C, Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007; 18: 352-8.
2. Quelhas R, Lopes A. Psychiatric problems in patients infected with hepatitis C before and during antiviral treatment with interferon-alpha: a review. J Psychiatr Pract 2009; 15: 262-81.
3. Schaefer M, Schmidt F, Folwaczny C, et al. Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups. Hepatology 2003; 37: 443-51.
4. Marsden J, Gossop M, Stewart D, Rolfe A, Farrell M. Psychiatric symptoms among clients seeking treatment for drug dependence - intake data from the National Treatment Outcome Research Study. Br J Psychiatry 2000; 176: 285-9.
5. Reimer J, Haasen C. Need-adapted HCV-treatment setting for injection drug users. Lancet 2009; 373: 2090-1.
6. Schulte B, Schutt S, Brack J, et al. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug Alcohol Depend 2010; 109: 248-51.
7. Schaefer M, Heinz A, Backmund M. Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules? Addiction 2004; 99: 1167-75.
8. Liu SS, Schneekloth TD, Talwalkar JA, et al. Impact of depressive symptoms and their treatment on completing antiviral treatment in patients with chronic hepatitis C. J Clin Gastroenterol 2010; 44:E178-85.
9. Mueser KT, Corrigan PW, Hilton DW, et al. Illness management and recovery: a review of the research. Psychiatr Serv 2002; 53: 1272-84.
10. Kuhn S, Farnbacher G, Verthein U, Krausz M, Haasen C. Psychoeducation within the German heroin trial - an innovative treatment approach. Suchttherapie 2007; 8: 26-32.
11. Zeuzem S. Standard treatment of acute and chronic hepatitis C. Z Gastroent 2004; 42: 714-9.
12. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.
13. Derogatis LR. Brief Symptom Inventory (BSI), administration, scoring, and procedures manual. 3rd ed. Minneapolis, MN: National Computer Services, 1993.
14. Das bundesdeutsche Modellprojekt zur heroingestützten Behandlung Opiatabhängiger - band 3 (the German model project for heroin assisted treatment of opioid dependent patients - vol 3). Baden-Baden: Nomos Verlagsgesellschaft mbH & Co. KG, Bundesministerium für Gesundheit, 2007.
15. Nagelkerke NJD. A note on a general definition of the coefficient of determination. Biometrika 1991; 78: 691-2.
16. Hadziyannis SJ, Sette H, Morgan TR, et al. Peginterferon-alpha 2a and ribavirin combination therapy in chronic hepatitis C - a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.
17. Bruggmann P, Falcato L, Dober S, et al. Active intravenous drug use during chronic hepatitis C therapy does not reduce sustained virological response rates in adherent patients. J Viral Hepatitis 2008; 15: 747-52.
18. Manolakopoulos S, Deutsch MJ, Anagnostou O, et al. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver Int 2010; 30: 1454-60.
19. Vermehren J, Sarrazin C. New HCV therapies on the horizon. Clin Microbiol Infect 2011; 17: 122-34.